Sigyn Therapeutics IncOTCQB:SIGY
- LAST PRICE5.7500
- TODAY'S CHANGE (%)0.2500 (4.5455%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close5.7500 / 5.5000
- Day Range
- 52 Week Range
- Volume256
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SIGY |
|---|---|---|
| 09:43 ET | 117 | 5.75 |
| 11:26 ET | 100 | 5.75 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sigyn Therapeutics Inc | 6.7M | -1.5x | --- |
Arch Therapeutics Inc | 5.6M | -0.3x | --- |
Sharps Technology Inc | 4.9M | -0.4x | --- |
Dror Ortho-Design Inc | 4.3M | -1.0x | --- |
Pressure Biosciences Inc | 5.9M | -0.2x | --- |
Nu-Med Plus Inc | 3.4M | -43.5x | --- |
Company Information
Sigyn Therapeutics, Inc. (Sigyn) is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company’s development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.
Contact Information
- Headquarters
- 9190 W Olympic Blvd # 263BEVERLY HILLS, CA, United States 90212
- Phone
- 619-368-2000
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- James Joyce
- Chief Financial Officer
- Jerry Deciccio
- Chief Technology Officer, Director
- Craig Roberts
- Independent Director
- Jim Dorst
- Independent Director
- Richa Nand
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.65 |
EPS | $-3.82 |
Book Value | $-2.65 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
